Avicanna Inc Report issue

For profit Phase 3
Founded: Toronto Canada (2016)

Organization Overview

First Clinical Trial
2020
NCT04613102
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Avicanna Inc

Active Ingredients

Drugs in Phase 3 Trials (1)

cannabidiol (Epidiolex) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Epidermolysis Bullosa (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1